We found that the treatment delayed tumor recurrence (Figure 7F) and blocked lung metastasis of the Brca1 mutant tumor (15.3%) compared to no treatment group (64.2%) (Figure 7G and Figure S9C, Supporting Information). The gene discussed is BRCA1; the disease is neoplasm.